Your gift is 100% tax deductible
Español
PDFs by language
Our 24/7 cancer helpline provides information and answers for people dealing with cancer. We can connect you with trained cancer information specialists who will answer questions about a cancer diagnosis and provide guidance and a compassionate ear.
Chat live online
Select the Live Chat button at the bottom of the page
Call us at 1-800-227-2345
Available any time of day or night
Our highly trained specialists are available 24/7 via phone and on weekdays can assist through online chat. We connect patients, caregivers, and family members with essential services and resources at every step of their cancer journey. Ask us how you can get involved and support the fight against cancer. Some of the topics we can assist with include:
For medical questions, we encourage you to review our information with your doctor.
Your gift enables us to support people with cancer and fund research breakthroughs.
The amount must be greater than or equal to $5
Your gift is 100% tax deductible
Research on bladder cancer is being done in many university hospitals, medical centers, and other institutions around the world. Each year, scientists find out more about what causes bladder cancer, how to find it as soon as possible, and how to better treat it.
Scientists have learned a lot about the differences between normal cells and bladder cancer cells. They're also learning how these differences help cancer cells grow and spread to other parts of the body.
Researchers are now developing tests to find gene or protein changes in bladder cancer cells that can help predict a person’s prognosis (outlook). These tests might also help doctors choose the best treatment, or help find bladder cancers that come back (recur) after treatment. Some of these types of biomarker tests are already being used (see Tests for Bladder Cancer), and others are now being tested.
Researchers also hope this knowledge can be used to develop new ways to treat bladder cancer, too.
Several newer tests look for substances (biomarkers) in urine that might show if a person has bladder cancer (see Tests for Bladder Cancer). At this time, these tests are used mainly to help diagnose bladder cancer or to look for cancer that has come back (cancer recurrence) in people who have already been treated.
Researchers are now studying if these tests might be helpful even earlier, to screen for bladder cancer in people who don't have symptoms. (See Can Bladder Cancer Be Found Early?)
Many advances in bladder cancer treatment have been made in recent years, and many newer types of treatment are now being studied. Here are some examples.
For non-muscle invasive bladder cancer, researchers are looking at many new medicines to see if putting them directly into the bladder after surgery can help lower the risk of the cancer coming back. The hope is to find some that are better and/or safer than currently used drugs. New drugs are also needed to treat bladder cancer that doesn't respond to intravesical BCG therapy.
Current studies are also looking at different ways to apply these treatments.
For example, studies are looking at:
See Intravesical Therapy for Bladder Cancer for more on how drugs are put right into the bladder to treat this cancer.
Some researchers are studying if photodynamic therapy (PDT) might be useful in treating early-stage bladder cancers. In PDT, a light-sensitive drug is injected into the blood. It collects in the cancer cells over a few days. Then a special type of laser light is focused on the inner lining of the bladder through a cystoscope. The light changes the drug in the cancer cells into a new chemical that can kill them.
An advantage of PDT is that it can kill cancer cells with very little harm to nearby normal cells. One drawback is that the chemical must be activated by light, so only cancers near the surface of the bladder lining can be treated in this way. The light can’t reach cancers that have grown deeper into the bladder wall or have spread to other organs.
PDT is already used to treat some other types of cancer. To learn more about this kind of treatment, see Photodynamic Therapy.
Cystectomy (removal of the bladder) is a common treatment for bladder cancer, especially if it invades the muscle layer of the bladder wall. Many surgeons now do robotic cystectomies. During these surgeries, they sit at a control panel in the operating room and move robotic arms attached to long, thin surgical instruments. This method lets the surgeon operate through several small cuts (incisions) in the abdomen instead of one large one. This tends to shorten the time a person needs to be in the hospital and helps them recover faster after surgery, although the long-term outcomes with this approach aren’t yet clear.
While cystectomy is often recommended to try to cure bladder cancer (especially if it has invaded the muscle layer in the bladder wall), removing a person’s bladder can have a profound effect on their quality of life. Doctors are now studying whether some newer approaches that don’t require removing the entire bladder might be just as effective.
For example, trimodality therapy, which includes an extensive transurethral resection of bladder tissue (TURBT), chemotherapy, and radiation therapy, is often an option for some people who can’t have or don’t want a cystectomy.
Researchers are now looking at whether adding newer medicines, such as immunotherapy drugs, might help make this treatment approach even more effective.
Advanced bladder cancers are hard to remove completely, so medicines are often used to try to shrink these tumors. Chemotherapy has been a mainstay of treatment for advanced bladder for many years. Unfortunately, some of the most effective chemo drugs, such as cisplatin, can have major side effects, and some people might not be healthy enough to get them. Even when chemo is given, it doesn’t always get rid of all of the cancer.
In recent years, some newer types of medicines have become an important part of the treatment for bladder cancer.
Immunotherapy drugs known as checkpoint inhibitors are now an important part of the treatment for many bladder cancers, either alone or combined with chemo or other drugs. Many newer types of immunotherapy are now being studied as well.
Antibody-drug conjugates (ADCs) are a newer type of medicine. They combine a chemo drug with an antibody that helps bring the chemo to the cancer cells, sparing normal cells. ADCs are now part of the treatment for many bladder cancers, and many newer ADCs are now being developed.
Many targeted therapy drugs are now being studied for use in bladder cancer. These medicines target specific parts of cancer cells that make them different from normal cells. Targeted therapy drugs work differently from standard chemo drugs. They may work in some cases when chemo drugs don’t, and they tend to have different side effects. As researchers are learning more about the changes in bladder cancer cells, these types of medicines are likely to become more important in treating bladder cancer.
While it’s unlikely that any single type of treatment will cure all bladder cancers, researchers are always looking at combining different types of treatment to see if this might be more effective. This might include some newer types of medicines (such as immunotherapy or targeted therapy), as well as treatments that have been used for many years, including surgery, radiation therapy, and chemotherapy.
The American Cancer Society medical and editorial content team
Our team is made up of doctors and oncology certified nurses with deep knowledge of cancer care as well as editors and translators with extensive experience in medical writing.
Black P, Kassouf W. Management of recurrent or persistent non-muscle invasive bladder cancer. UpToDate. 2023. Accessed at https://www.uptodate.com/contents/management-of-recurrent-or-persistent-non-muscle-invasive-bladder-cancer on November 16, 2023.
Crabb SJ, Douglas J. The latest treatment options for bladder cancer. Br Med Bull. 2018 Oct 29.
El-Achkar A, Souhami L, Kassouf W. Bladder preservation therapy: Review of literature and future directions of trimodal therapy. Curr Urol Rep. 2018;19(12):108.
National Cancer Institute. Advances in Bladder Cancer Research. 2023. Accessed at https://www.cancer.gov/types/bladder/research on November 16, 2023.
National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Bladder Cancer. Version 3.2023. Accessed at https://www.nccn.org/professionals/physician_gls/pdf/bladder.pdf on November 16, 2023.
Werntz RP, Adamic B, Steinberg GD. Emerging therapies in the management of high-risk non-muscle invasive bladder cancer (HRNMIBC). World J Urol. 2018 Dec 4.
Last Revised: March 12, 2024
American Cancer Society medical information is copyrighted material. For reprint requests, please see our Content Usage Policy.
Sign up to stay up-to-date with news, valuable information, and ways to get involved with the American Cancer Society.
We fund research breakthroughs that save lives. Your year-end gift helps find new treatments for cancer.